Treatment of prostate and lung cancer cells with the FASN inhibitor cerulenin or the palmitoylation inhibitor 2-bromopalmitate (2-BP) reduces EGFR levels on the plasma membrane while increasing lysosome levels (42). This evidence concerns the gene EGFR and lung carcinoma.